Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

The NHS in England and Wales finally has consensus on what tests can be used to determine if a lung cancer patient has the genetic mutation epidermal growth factor receptor (EGFR).

The National Institute for Health and Care Excellence (NICE) has produced guidance recommending several tests to detect the mutation, which is prevalent in between 10 to 15 per cent of Caucasian people with non-small cell lung cancer (NSLC) and 40 per cent of Asian people.

It is important to know if patients have the mutation as some treatments are more effective in this specific population.

These include Boehringer Ingelheim's Giotrif/ Gilotrif (afatinib) and Roche's Tarceva (erlotinib), both of which have specific approvals for use in patients with EGFR.

Both medicines were also approved by the US Food and Drug Administration (FDA) alongside companion diagnostics: Roche's own cobas EGFR Mutation Test for Tarceva and Qiagen's therascreen EGFR RGQ PCR Kit for Gilotrif.

Similar guidance has been lacking in Europe, but NICE has now made the effort to ensure appropriate patients are given access to these personalised treatments.

As such, both the Roche and Qiagen devices are recommended to detect EGFR in patients, although neither is suggested for use alongside a specific medicine.

“We know that patients whose tumours are positive for the EGFR mutation and who are given an EGFR-TK inhibitor gain more benefit than from standard chemotherapy treatment,” explained Professor Carole Longson, NICE Health Technology Evaluation Centre director.

“We also know that patients without the EGFR mutation do not respond as well if they are given these drugs instead of standard chemotherapy.

“It is important, therefore, to ensure high accuracy of testing, particularly to minimise the chances of incorrect treatment as a result of a false-positive or false-negative test results, in order to improve outcomes for patients with lung cancer.”

Article by
Thomas Meek

14th August 2013

From: Sales, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics